StockData
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. (EWTX) stock

EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$42.04−1.64 (-3.75%)

Close on Nov 17, 2026Market cap $4.57BP/E –Yield –

Edgewise Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Edgewise Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $171.27M, up 23.3% year over year. For fiscal 2025 it was $151.39M, up 19.2% from the year before. The highest annual figure on record is $151.39M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$151.39M+19.2%
FY2024Dec 31, 2024$126.97M+39.7%
FY2023Dec 31, 2023$90.91M+68.2%
FY2022Dec 31, 2022$54.03M+67.9%
FY2021Dec 31, 2021$32.19M+114.8%
FY2020Dec 31, 2020$14.98M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$47.55M+41.7%
Q1 FY2026Mar 31, 2026$42.65M+16.0%
Q4 FY2025Dec 31, 2025$43.59M+19.9%
Q3 FY2025Sep 30, 2025$37.48M+16.3%
Q2 FY2025Jun 30, 2025$33.56M+9.4%
Q1 FY2025Mar 31, 2025$36.76M+32.7%
Q4 FY2024Dec 31, 2024$36.37M+31.4%
Q3 FY2024Sep 30, 2024$32.22M+35.5%
Q2 FY2024Jun 30, 2024$30.68M+56.9%
Q1 FY2024Mar 31, 2024$27.69M+39.3%
Q4 FY2023Dec 31, 2023$27.68M+66.7%
Q3 FY2023Sep 30, 2023$23.79M+71.2%
Q2 FY2023Jun 30, 2023$19.56M+57.7%
Q1 FY2023Mar 31, 2023$19.88M+78.7%
Q4 FY2022Dec 31, 2022$16.61M+82.8%
Q3 FY2022Sep 30, 2022$13.89M+40.6%
Q2 FY2022Jun 30, 2022$12.40M+57.8%
Q1 FY2022Mar 31, 2022$11.12M+107.5%
Q4 FY2021Dec 31, 2021$9.09M+76.8%
Q3 FY2021Sep 30, 2021$9.88M+205.1%
Q2 FY2021Jun 30, 2021$7.86M+116.0%
Q1 FY2021Mar 31, 2021$5.36M+80.7%
Q4 FY2020Dec 31, 2020$5.14M–
Q3 FY2020Sep 30, 2020$3.24M–
Q2 FY2020Jun 30, 2020$3.64M–
Q1 FY2020Mar 31, 2020$2.97M–

More Edgewise Therapeutics figures

See a number that looks wrong?